Related Experiment Video

Updated: May 23, 2026

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes
07:32

Analysis of Cardiac Contractile Dysfunction and Ca2+ Transients in Rodent Myocytes

Published on: May 25, 2022

Leukocyte and cardiac phosphoinositide 3-kinase γ activity in pressure overload-induced cardiac failure

Alessia Perino1, Alessandra Ghigo, Emilio Hirsch

  • 1Department of Genetics, Biology and Biochemistry, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy.

Trends in Cardiovascular Medicine
|March 22, 2012
PubMed

Insights

Phosphoinositide 3-kinase p110γ (PI3K p110γ) regulates immune cells and heart function. Targeting PI3K p110γ offers potential for treating heart failure by modulating cardiac remodeling and inflammation.

Area of Science:

  • Cardiovascular Biology
  • Immunology
  • Pharmacology

Background:

  • Phosphoinositide 3-kinase p110γ (PI3K p110γ) is crucial for leukocyte and cardiomyocyte functions.
  • PI3K p110γ controls leukocyte chemotaxis and inflammation, and influences cardiac β-adrenergic receptor signaling.
  • The link between inflammatory responses and cardiac dysfunction highlights PI3K p110γ as a therapeutic target for heart failure.

Purpose of the Study:

  • To review recent findings on the role of PI3K p110γ in cardiac remodeling.
  • To differentiate the contributions of leukocyte-specific and cardiomyocyte-specific PI3K p110γ.
  • To explore therapeutic implications for heart failure treatment.

Main Methods:

  • Review of recent scientific literature.
  • Analysis of studies investigating pressure overload-induced cardiac remodeling.
  • Examination of the role of PI3K p110γ in both immune and cardiac cells.

Main Results:

  • PI3K p110γ plays a significant role in the progression of cardiac remodeling.
  • Both leukocyte and cardiomyocyte PI3K p110γ contribute to pressure overload-induced heart dysfunction.
  • Understanding these distinct roles is key to developing targeted therapies.

Conclusions:

  • PI3K p110γ is a critical mediator in the development of heart failure.
  • Targeting PI3K p110γ, considering its dual role in immune and cardiac cells, presents a promising therapeutic strategy.
  • Further research is warranted to fully elucidate the therapeutic potential in heart failure.

More Related Videos

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure07:13

A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure

Published on: April 30, 2020

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...